EOLS News
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
Zacks
UTMD Trades at a Premium to the Industry: How to Play the Stock?
Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.
Zacks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is...
PR Newswire
Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug
The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.read more...
Benzinga
Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support...
Business Wire
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture PR Newswire NEW YORK, Sept. 1, 2026 NEW...
PR Newswire
Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet
The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 106.1% in Evolus (EOLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2
Evolus (EOLS) delivered earnings and revenue surprises of +100.00% and +2.59%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2026. The increasing momentum of our portfolio focus has resulted in Evolus gaining...
Business Wire